Last reviewed · How we verify
BHV-2100
BHV-2100 is a calcitonin gene-related peptide receptor antagonist.
BHV-2100 is a calcitonin gene-related peptide receptor antagonist. Used for Migraine prevention.
At a glance
| Generic name | BHV-2100 |
|---|---|
| Sponsor | Biohaven Therapeutics Ltd. |
| Drug class | CGRP receptor antagonist |
| Target | CGRP receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
BHV-2100 works by blocking the action of calcitonin gene-related peptide (CGRP) at its receptor, which is involved in the transmission of pain signals. This mechanism is thought to be beneficial in the treatment of migraine and other headache disorders.
Approved indications
- Migraine prevention
Common side effects
- Injection site reactions
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BHV-2100 CI brief — competitive landscape report
- BHV-2100 updates RSS · CI watch RSS
- Biohaven Therapeutics Ltd. portfolio CI